Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $544.94, generating approximately $5.18 million. Her remaining stake totaled 324,443 shares, valued at about $176.8 million.
- United Therapeutics reported quarterly EPS of $7.27, exceeding analysts’ $6.86 estimate, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analyst sentiment remains broadly positive, with 11 Buy ratings, two Holds and one Sell; the stock has a “Moderate Buy” consensus and an average price target of $627.31.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $544.94, for a total value of $5,176,930.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $176,801,968.42. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
United Therapeutics Trading Down 1.2%
Shares of NASDAQ:UTHR opened at $543.40 on Wednesday. The stock has a market capitalization of $23.31 billion, a P/E ratio of 19.44, a P/E/G ratio of 3.94 and a beta of 0.49. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The business has a 50-day moving average price of $513.17 and a two-hundred day moving average price of $540.27.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $6.41 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 26.40 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a research note on Thursday, September 24th. They issued a "sell" rating and a $321.00 price objective on the stock. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $677.00 to $708.00 and gave the company an "outperform" rating in a research report on Thursday, October 8th. Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $627.31.
Check Out Our Latest Stock Report on UTHR
Hedge Funds Weigh In On United Therapeutics
Several institutional investors have recently modified their holdings of UTHR. BlackRock Inc. bought a new position in United Therapeutics during the 2nd quarter worth approximately $2,868,735,000. Janus Henderson Group PLC grew its holdings in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Jupiter Topco LLC bought a new stake in United Therapeutics in the second quarter valued at approximately $450,140,000. Swedbank AB increased its stake in United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company's stock valued at $193,977,000 after purchasing an additional 2,350 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in United Therapeutics by 0.8% in the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company's stock valued at $183,306,000 after purchasing an additional 2,383 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
